verapamil has been researched along with 2019 Novel Coronavirus Disease in 6 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Medical history was notable for hypertension, hyperlipidaemia, type 2 diabetes, and a recently diagnosed SARS-CoV-2 (COVID-19) infection for which she was prescribed ritonavir-boosted nirmatrelvir (Paxlovid) two days before the presentation." | 8.31 | Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension. ( Haque, OI; Hussain, S; Mahar, S; Sloane, P, 2023) |
| " Medical history was notable for hypertension, hyperlipidaemia, type 2 diabetes, and a recently diagnosed SARS-CoV-2 (COVID-19) infection for which she was prescribed ritonavir-boosted nirmatrelvir (Paxlovid) two days before the presentation." | 4.31 | Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension. ( Haque, OI; Hussain, S; Mahar, S; Sloane, P, 2023) |
| "The incidence of COPD patients is gradually increasing, especially in patients over 45 years old." | 1.72 | Bioinformatics Approach Predicts Candidate Targets for SARS-CoV-2 Infections to COPD Patients. ( Cai, X; Che, L; Chen, G; Liu, S; Xia, T; Xie, Z; Zhang, W, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rengasamy, ER | 1 |
| Long, SA | 1 |
| Rees, SC | 1 |
| Davies, S | 1 |
| Hildebrandt, T | 1 |
| Payne, E | 1 |
| Che, L | 1 |
| Chen, G | 1 |
| Cai, X | 1 |
| Xie, Z | 1 |
| Xia, T | 1 |
| Zhang, W | 1 |
| Liu, S | 1 |
| Navarese, EP | 2 |
| Podhajski, P | 1 |
| Andreotti, F | 1 |
| La Torre, G | 1 |
| Gajda, R | 1 |
| Radziwanowski, A | 1 |
| Nowicka, M | 1 |
| Bukowski, P | 1 |
| Gajda, J | 1 |
| Omyła, M | 1 |
| Lackowski, P | 1 |
| Piasecki, M | 1 |
| Jasiewicz, M | 1 |
| Szymański, P | 1 |
| Pietrzykowski, Ł | 1 |
| Michalski, P | 1 |
| Kubica, A | 1 |
| Urbanowicz, I | 1 |
| Orsini, N | 1 |
| Conte, M | 1 |
| Pinkas, J | 1 |
| Brouwer, MA | 1 |
| Kubica, J | 2 |
| Haque, OI | 1 |
| Mahar, S | 1 |
| Hussain, S | 1 |
| Sloane, P | 1 |
| Gómez-Enjuto, S | 1 |
| Hernando-Requejo, V | 1 |
| Lapeña-Motilva, J | 1 |
| Ogando-Durán, G | 1 |
| Fouz-Ruiz, D | 1 |
| Domingo-García, J | 1 |
| Rodríguez-García, E | 1 |
| Cemillán-Fernández, CA | 1 |
| Musci, RL | 1 |
| Frediani, L | 1 |
| Gurbel, PA | 1 |
1 review available for verapamil and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Ion channel inhibition against COVID-19: A novel target for clinical investigation.
Topics: Amiodarone; Communicable Disease Control; Coronavirus Infections; COVID-19; Female; Humans; Ion Chan | 2020 |
1 trial available for verapamil and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial.
Topics: Amiodarone; C-Reactive Protein; Carbidopa; COVID-19; Drug Combinations; Humans; Ion Channels; Levodo | 2022 |
4 other studies available for verapamil and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Impact of COVID-19 lockdown: Domestic and child abuse in Bridgend.
Topics: Child; Child Abuse; Communicable Disease Control; COVID-19; Humans; Pandemics; Retrospective Studies | 2022 |
Bioinformatics Approach Predicts Candidate Targets for SARS-CoV-2 Infections to COPD Patients.
Topics: Artesunate; Computational Biology; COVID-19; Gene Expression Profiling; Gene Regulatory Networks; Hu | 2022 |
Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension.
Topics: Bradycardia; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Female; Humans; Hypertens | 2023 |
Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient.
Topics: Aged; Anemia; Anticoagulants; Anticonvulsants; Antiviral Agents; Betacoronavirus; Calcium Channel Bl | 2020 |